Home > Boards > Free Zone > Health and Sciences > Biotech Values

Is ASMB now a buy? It depends! ASMB—$5.15—trading

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 751
Posts 115,762
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
DewDiligence Member Level  Friday, 11/06/20 03:14:08 PM
Re: RNsidersbuying post# 235471
Post # of 238047 
Is ASMB now a buy? It depends!
Quote:
ASMB—$5.15—trading down to cash level...took a first position.

From an investment (rather than trading) perspective, buying now is reasonable if you think one of ASMB’s two follow-on CpAM agents, which are more potent than ABI-H0731, will eventually work out.

On the other hand, I strongly disagree with ASMB’s decision to continue plans for phase-2 and phase-3 trials of ABI-H0731 with other agents in pursuit of the “inadequate chronic suppression” market. Even if adding ABI-H0731 to a regimen nominally succeeds by getting these patients to undetectable viral load, the clinical benefit of such an outcome is unclear and getting reimbursement for such an indication will be a tall order, IMO.

In other words, it looks like ASMB is succumbing to Zebra’s Law.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences